Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer

被引：2
|
作者：
Torres, Alexandra
Kokkonen, Carey
Oladeji, Mary
D'Andrea, Kurt
Mick, Rosemarie
Narayan, Vivek
Mallamaci, Michael
Ewing, Gayle
Knollman, Hayley
Tung, Nadine M.
Robson, Mark
Nathanson, Katherine L.
Domchek, Susan
Shah, Payal D.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-OT2-18-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-18-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
    Nicolò Matteo Luca Battisti
    Belinda Kingston
    Judy King
    Arshi Denton
    Simon Waters
    Ailsa Sita-Lumsden
    Farah Rehman
    Chara Stavraka
    Hartmut Kristeleit
    Elinor Sawyer
    David Houghton
    Neville Davidson
    Sacha Howell
    Julia Choy
    Peter Harper
    Rebecca Roylance
    Raja Fharat
    Kabir Mohammed
    Alistair Ring
    Stephen Johnston
    Breast Cancer Research and Treatment, 2019, 174 : 731 - 740
  • [32] Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
    Malorni, L.
    Curigliano, G.
    Minisini, A. M.
    Cinieri, S.
    Tondini, C. A.
    D'Hollander, K.
    Arpino, G.
    Bernardo, A.
    Martignetti, A.
    Criscitiello, C.
    Puglisi, F.
    Pestrin, M.
    Sanna, C.
    Moretti, E.
    Risi, E.
    Biagioni, C.
    McCartney, A.
    Boni, L.
    Buyse, M.
    Migliaccio, I.
    Biganzoli, L.
    Di Leo, A.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1748 - 1754
  • [33] PALOMA3: Phase 3 trial of fulvestrant with or without palbociclib in pre and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy-confirmed efficacy and safety
    Cristofanilli, M.
    Bondarenko, I.
    Ro, J.
    Im, S-A
    Masuda, N.
    Colleoni, M.
    DeMichele, A. M.
    Loi, S.
    Verma, S.
    Iwata, H.
    Bartlett, C. Huang
    Zhang, K.
    Theall, K. Puyana
    Turner, N. C.
    Slamon, D. J.
    CANCER RESEARCH, 2016, 76
  • [34] Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
    Battisti, Nicolo Matteo Luca
    Kingston, Belinda
    King, Judy
    Denton, Arshi
    Waters, Simon
    Sita-Lumsden, Ailsa
    Rehman, Farah
    Stavraka, Chara
    Kristeleit, Hartmut
    Sawyer, Elinor
    Houghton, David
    Davidson, Neville
    Howell, Sacha
    Choy, Julia
    Harper, Peter
    Roylance, Rebecca
    Fharat, Raja
    Mohammed, Kabir
    Ring, Alistair
    Johnston, Stephen
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) : 731 - 740
  • [35] A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer
    Cescon, David W.
    Hilton, John
    Morales Murilo, Serafin
    Layman, Rachel M.
    Pluard, Timothy
    Yeo, Belinda
    Park, In Hae
    Provencher, Louise
    Kim, Sung-Bae
    Im, Young-Hyuck
    Wyce, Anastasia
    Krishnatry, Anu Shilpa
    Hicks, Kirsty
    Zhang, Qu
    Barbash, Olena
    Khaled, Ahmed
    Horner, Thierry
    Dhar, Arindam
    Oliveira, Mafalda
    Sparano, Joseph A.
    CLINICAL CANCER RESEARCH, 2024, 30 (02) : 334 - 343
  • [36] Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
    Lorenzo Rossi
    Chiara Biagioni
    Amelia McCartney
    Ilenia Migliaccio
    Giuseppe Curigliano
    Giuseppina Sanna
    Erica Moretti
    Alessandro M. Minisini
    Saverio Cinieri
    Carlo Tondini
    Grazia Arpino
    Antonio Bernardo
    Angelo Martignetti
    Emanuela Risi
    Marta Pestrin
    Luca Boni
    Matteo Benelli
    Laura Biganzoli
    Angelo Di Leo
    Luca Malorni
    Breast Cancer Research, 21
  • [37] Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
    Rossi, Lorenzo
    Biagioni, Chiara
    McCartney, Amelia
    Migliaccio, Ilenia
    Curigliano, Giuseppe
    Sanna, Giuseppina
    Moretti, Erica
    Minisini, Alessandro M.
    Cinieri, Saverio
    Tondini, Carlo
    Arpino, Grazia
    Bernardo, Antonio
    Martignetti, Angelo
    Risi, Emanuela
    Pestrin, Marta
    Boni, Luca
    Benelli, Matteo
    Biganzoli, Laura
    Di Leo, Angelo
    Malorni, Luca
    BREAST CANCER RESEARCH, 2019, 21 (1):
  • [38] Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
    Mao, Yan
    Lv, Meng
    Wang, Yongmei
    Cao, Weihong
    Li, Wenfeng
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [39] The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis
    Zhang, Linhui
    Song, Guohong
    Shao, Bin
    Xu, Ling
    Xiao, Yu
    Wang, Mopei
    Sumou, Ingrid Karmane
    Zhang, Yan
    Liang, Xu
    Jiang, Hanfang
    Li, Huiping
    ANTI-CANCER DRUGS, 2022, 33 (01) : E635 - E643
  • [40] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
    Pernas, Sonia
    Sanfeliu, Esther
    Villacampa, Guillermo
    Salvador, Javier
    Perello, Antonia
    Gonzalez, Xavier
    Jimenez, Begona
    Merino, Maria
    Palacios, Patricia
    Pascual, Tomas
    Alba, Emilio
    Villanueva, Lorea
    Chillara, Samyukta
    Ferrero-Cafiero, Juan Manuel
    Galvan, Patricia
    Prat, Aleix
    Ciruelos, Eva
    NPJ BREAST CANCER, 2024, 10 (01)
12345